U.S. markets close in 1 hour 37 minutes
  • S&P 500

    4,134.04
    -39.38 (-0.94%)
     
  • Dow 30

    33,786.43
    -350.88 (-1.03%)
     
  • Nasdaq

    13,812.85
    -137.37 (-0.98%)
     
  • Russell 2000

    2,229.76
    -9.86 (-0.44%)
     
  • Crude Oil

    61.19
    -0.16 (-0.26%)
     
  • Gold

    1,780.10
    -13.00 (-0.73%)
     
  • Silver

    26.06
    -0.51 (-1.92%)
     
  • EUR/USD

    1.2002
    -0.0038 (-0.31%)
     
  • 10-Yr Bond

    1.5540
    -0.0100 (-0.64%)
     
  • GBP/USD

    1.3828
    -0.0104 (-0.75%)
     
  • USD/JPY

    108.1220
    +0.0790 (+0.07%)
     
  • BTC-USD

    53,169.23
    -2,603.44 (-4.67%)
     
  • CMC Crypto 200

    1,243.92
    +0.86 (+0.07%)
     
  • FTSE 100

    6,938.24
    +42.95 (+0.62%)
     
  • Nikkei 225

    29,188.17
    +679.62 (+2.38%)
     

Chimerix's DSTAT Shows Promising Results In First Cohort Of COVID-19 Study

  • Oops!
    Something went wrong.
    Please try again later.
Vandana Singh
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Chimerix Inc (NASDAQ: CMRX) reports topline results from the first cohort (n=12) of its Phase 2/3 study evaluating DSTAT in hospitalized patients with Acute Lung Injury (ALI) and COVID-19 infection.

  • The primary endpoint of the study is survival without the need for mechanical ventilation through day 28. One patient on DSTAT was ventilated and recovered, and two patients on placebo progressed to ventilation and died.

  • No deaths were reported in patients on the DSTAT arm.

  • All six DSTAT patients met the clinical status assessment's improvement criteria, compared to two of the six placebo patients.

  • No patients on DSTAT had elevated values for biomarkers related to lung inflammation and thrombotic complications.

  • DSTAT was observed to be generally safe and well-tolerated. No patients on the DSTAT arm discontinued study treatment for adverse events compared to two patients on the placebo arm.

  • The second cohort of 12 patients is fully enrolled, with topline data expected in the second quarter.

  • Price Action: CMRX shares are down 1.77% at $10 in the premarket session on the last check Thursday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.